Literature DB >> 12854903

Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia.

Patricia A Goodman1, Carla M Wood, Alexei O Vassilev, Chen Mao, Fatih M Uckun.   

Abstract

Bruton's tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase that serves an essential role in B cell signaling and development. We examined the BTK expression profile of primary leukemic cells from infants with newly diagnosed acute lymphoblastic leukemia (ALL) (N = 14) and from pediatric patients with newly diagnosed (N = 10) or relapsed (N = 5) B-lineage ALL. Analysis of BTK protein and mRNA expression in the infant patient cells (N = 14) showed variable levels of BTK expression with the majority of samples having reduced to absent BTK expression. Sequence analysis of reverse transcriptase-polymerase chain reaction (RT-PCR) products of Btk mRNA from infant leukemia cells revealed the presence of aberrant transcripts. These Btk transcripts were characterized by either deletion of exon 16 (delta16) alone or deletion of both exons 15 and 16 (delta15 and 16). These deletions involve exact exon skipping and encode BTK proteins with either a deleted (delta16), or truncated (delta15 and 16) kinase domain. Extension of these Btk transcript sequencing studies to 15 pediatric B-lineage ALL patients revealed expression of exon 16 deleted Btk transcripts in several pediatric patients, however, none of these pediatric patients expressed transcripts with the exon 15 and 16 deletion. Both reduced expression of Btk message and expression of aberrant deleted Btk transcripts would contribute to reduced BTK protein expression and function in B-lineage leukemia cells. Since BTK is required for radiation induced apoptosis, reduced to absent expression of functional BTK in infant ALL cells could contribute to their radiation resistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12854903     DOI: 10.1080/1042819031000067576

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  10 in total

1.  Are patients with X-linked agammaglobulinemia at increased risk of developing acute lymphoblastic leukemia?

Authors:  Mary Ellen Conley
Journal:  J Clin Immunol       Date:  2015-01-29       Impact factor: 8.317

2.  Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells.

Authors:  Niklas Feldhahn; Paula Río; Bonaventure Ndikung Bejeng Soh; Stefanie Liedtke; Mieke Sprangers; Florian Klein; Peter Wernet; Hassan Jumaa; Wolf-Karsten Hofmann; Helmut Hanenberg; Janet D Rowley; Markus Müschen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-02       Impact factor: 11.205

3.  Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK.

Authors:  Ekaterina Kim; Christian Hurtz; Stefan Koehrer; Zhiqiang Wang; Sriram Balasubramanian; Betty Y Chang; Markus Müschen; R Eric Davis; Jan A Burger
Journal:  Blood       Date:  2016-12-28       Impact factor: 22.113

4.  Discovery and biological evaluation of N5-substituted 6,7-dioxo-6,7-dihydropteridine derivatives as potent Bruton's tyrosine kinase inhibitors.

Authors:  Haiyang Chen; Peiran Song; Yanyan Diao; Yongjia Hao; Dou Dou; Wanqi Wang; Xiaoyu Fang; Yanling Wang; Zhenjiang Zhao; Jian Ding; Honglin Li; Hua Xie; Yufang Xu
Journal:  Medchemcomm       Date:  2018-03-13       Impact factor: 3.597

Review 5.  The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia.

Authors:  J Eswaran; P Sinclair; O Heidenreich; J Irving; L J Russell; A Hall; D P Calado; C J Harrison; J Vormoor
Journal:  Leukemia       Date:  2015-05-06       Impact factor: 11.528

6.  Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells.

Authors:  Niklas Feldhahn; Florian Klein; Jana L Mooster; Paul Hadweh; Mieke Sprangers; Maria Wartenberg; Mohamed M Bekhite; Wolf-Karsten Hofmann; Sebastian Herzog; Hassan Jumaa; Janet D Rowley; Markus Müschen
Journal:  J Exp Med       Date:  2005-06-06       Impact factor: 14.307

Review 7.  Ibrutinib and novel BTK inhibitors in clinical development.

Authors:  Akintunde Akinleye; Yamei Chen; Nikhil Mukhi; Yongping Song; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-08-19       Impact factor: 17.388

Review 8.  Targeting Bruton's tyrosine kinase in B cell malignancies.

Authors:  Rudi W Hendriks; Saravanan Yuvaraj; Laurens P Kil
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

9.  Regulatory phosphorylation of Ikaros by Bruton's tyrosine kinase.

Authors:  Hong Ma; Sanjive Qazi; Zahide Ozer; Jian Zhang; Rita Ishkhanian; Fatih M Uckun
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

Review 10.  Targeted genome editing in acute lymphoblastic leukemia: a review.

Authors:  Adrián Montaño; Maribel Forero-Castro; Jesús-María Hernández-Rivas; Ignacio García-Tuñón; Rocío Benito
Journal:  BMC Biotechnol       Date:  2018-07-17       Impact factor: 2.563

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.